Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA But Without Clinically Detectable Residual Diseases and/or Metastases After Curative Chemoradiation - A Single Arm Phase II Trial

NCT03544099 is registered in ClinicalTrials.gov with National Health Research Institutes, Taiwan as lead sponsor.

NCT NCT03544099
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03544099 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA But Without Clinically Detectable Residual Diseases and/or Metastases After Curative Chemoradiation - A Single Arm Phase II Trial
Lead sponsor
National Health Research Institutes, Taiwan
Phase
Phase 2
Overall status
Terminated
Start date
May 7, 2019
Completion date
December 31, 2021
Enrollment
2 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

nasopharyngeal carcinoma